Antibacterial and anticancer potential of Brassica oleracea var acephala using biosynthesised copper nanoparticles

@#ary phytochemical screening. The resultsshowed that the ethanolic crude extract of the leaf containhigh phytochemical activity hence B.oleraceavaracephalais rich in flavonoids, phenolic compounds, carbohydratesand phytosterols. Materials and methods: The ethanolic extract was used tosynthesise copper nanoparticles. The copper nanoparticleswere successfully synthesised from copper sulphatesolution which was identified by the colour change fromdark green colour of the extract. Thus the B.oleracea varacephala is a good source to synthesis coppernanoparticles. The synthesised copper nanoparticles werecharacterised using Scanning Electron Microscope (SEM)analysis. The SEM image displayed the high-densitynanoparticles synthesised by leaf extracts and that thenanoparticles were crystals in shape. Results: The copper nanoparticles (CNP) bind to the leafextract. B.oleraceavaracephalaalso has shown theantimicrobial and antioxidant activity. A comparative studywas done between ethanolic its crude extract andnanoparticles. Both extracts exhibited zone of inhibition andbetter antioxidant potential but the CuNPs shows majorzone of inhibition and showed more antioxidant activity.Anticancer activity of B.oleraceavaracephalaagainstCervical HeLa cell line was confirmed using ethanolic crudeextract and CNP. The results showed that HeLa cellsproliferation was inhibited with increasing concentration ofethanolic crude extract and copper nanoparticles. From theresults, it was seen that percentage viability of the cancercells decreased with increased concentration of the sampleswhereas cytotoxicity against HeLa cell lines increased withthe increased concentration of the samples. Conclusion: Thus B.oleraceavaracephalapossessesanticancer activity against HeLa cell lines.

Bubble continuous positive airway pressure therapy for neonatal respiratory distress at birth in level III newborn unit in Chengalpattu Medical College Hospital: a prospective observational study

Background: Bubble continuous positive airway pressure (bCPAP), a non-invasive respiratory device provides continuous pressure that helps recruitment of more alveoli, increases the lungs, functional residual capacity and decreases the work of breathing in newborns admitted with respiratory distress. Bubble continuous positive airway pressure (bCPAP) is the most important respiratory support in different types of respiratory conditions in level III. In this observational study, author reported this research using bCPAP therapy as the primary respiratory support in level III unit in tertiary care centre in Chengalpattu, Tamil Nadu, India. Despite reporting their indications, duration of use and adverse effects we tried to search for further improvement in other areas of CPAP therapy in level III newborn unit.Methods: This prospective observational study included 250 babies delivered in obstetric unit and admitted with respiratory distress within 6 hours of birth at level III care. They were treated according to level III newborn unit protocol. Those data were collected and entered in the proforma. Newborns were followed up till discharge.Results: A total of 250 babies satisfying the inclusion criteria delivered in Chengalpattu Medical College Hospital, Tamil Nadu, India (mean gestational age 36'2 weeks, mean birth weight 2.5'1.2 kg were included. All newborns were given bCPAP as the primary support. The most common underlying cause of respiratory distress was transient tachypnea of newborn (44%), followed by respiratory distress syndrome (24%) and prolonged respiratory transition (18%). The therapy success rate was 86%. Only 35 newborns failed to respond to CPAP. The most common adverse effect was eye puffiness (19%).Conclusions: Bubble continuous positive airway pressure (b CPAP) therapy use is being well established in level III unit for various respiratory conditions with minimal failure and adverse effects. Its use in extreme preterms and initiation after 6 hours is controversial.

Outcome of Chemotherapeutic Regimens Cisplatin and 5-Fluorouracil vs Weekly 5-Fluorouracil in Advanced Gastric Cancer

Introduction: Gastric cancer is the second leading cause ofcancer death worldwide, with a 5-year survival rate of lessthan 20%. About 25% of patients with gastric cancer presentwith disseminated disease and more than half of those withapparently localized disease recur within 5 years. Study aimedto evaluate the response rate, median PFS, overall survivaland toxicity to 3 Weekly Cisplatin/5-Fluorouracil Vs Weekly5-Fluorouracil in patients with advanced gastric cancer.Material and Methods: Patients were recruited forchemotherapy with Cisplatin 75mg/mg2 in divided dosesand 5-Fluorouracil 750mg/m2 for 3 days in every 21 daysfor 6 cycles in one arm and 20 patients for treatment withWeekly 5- Fluorouracil 500mg for 16 weeks. Within twomonths of completion of chemotherapy, CT abdomen wasdone to compare with the baseline CT abdomen to assess theresponse rate using RESIST criteria Version V1.1. Also theimprovement in ECOG PS was ascertained as an endpoint.Results: In the Cisplatin /5FU arm had an overall response rateof 20%, median PFS of 6 months,45% had a partial response(PR), 10% had stable disease (SD) 25% had progression(PD), 20% achieved CR and more of haematological andnon-hematological toxicity. In the 5FU arm, 35% had stabledisease (SD),40% had progression (PD) 5% achieved CR andless of haematological and non-hematological toxicity.Conclusion: In advanced gastric cancer, Cisplatin /5FU hadmore response rate, more median PFS and more toxicity.Weekly 5FU is better tolerable regimen with